



ASX Release

18 September 2017

ZELDA THERAPEUTICS LIMITED
ACN 103 782 378

Level 45
108 St Georges Terrace,
Perth Western Australia 6000
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeldatherapeutics.com
Web: www.zeldatherapeutics.com

Contacts

Corporate

Mr Harry Karelis
Executive Chairman
+61 413 056 328
hkarelis@zeldatherapeutics.com

Investors

Dr Stewart Washer
Executive Director
+61 418 288 212
swasher@zeldatherapeutics.com

Directors

Mr Harry Karelis
Dr Stewart Washer
Ms Mara Gordon
Mr Jason Peterson

ASX Code:

ZLD

Ordinary Shares:

754,841,934

Options:

48,000,000

6,000,000 (\$0.04 - 6/2/2020 -
subject to vesting conditions)
2,000,000 (\$0.04 - 6/2/2020)
40,000,000 (\$0.03125-17/11/2021)

**UPDATE ON CLOSING DATE OF PRIORITY OFFER OF CANNPAL ANIMAL
THERAPEUTICS LIMITED'S PROSPECTUS**

Zelda Therapeutics Limited (**ASX: ZLD, Zelda** or the **Company**) advises that on the basis of the applications received to date, CannPal Animal Therapeutics Limited (**CannPal**) is seeking to bring forward the closing date of its Offer and the Priority Offer to eligible Zelda shareholders in its Prospectus dated 28 August 2017.

The Directors have advised CannPal that Zelda does not object to amending the closing date for the Priority Offer and have been advised that CannPal has resolved to bring the closing date of the Priority Offer forward to Friday, 22 September 2017. Therefore, eligible Zelda shareholders who intend to make an application under the Priority Offer will now need to do so by the close of business this **Friday, 22 September 2017**.

In order to participate in the Priority Offer, you will need to follow the instructions on the Application Form attached to the CannPal Prospectus. More information on CannPal can be found via their website at www.cannpal.com and in the Prospectus.

This announcement is not an offer for subscription, invitation, recommendation or sale of shares for or on behalf of CannPal and Shareholders should note that Zelda is not making any endorsement of the CannPal Prospectus and makes no representation or warranty, express or implied in relation to the accuracy or completeness of the information provided in the CannPal Prospectus. No responsibility is accepted by Zelda or any of its representatives, directors, partners, employees or professional advisers for any information provided in the CannPal Prospectus or for any action taken by the recipients on the basis of such information. Each recipient of the information should make its own independent assessment of the information and take its own independent professional advice in relation to the information and any action taken on the basis of the information.

Tim Slate
Company Secretary

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics ("Zelda") is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-pronged strategy comprising:

- A human clinical trial programme focused on insomnia, autism and eczema with activities in Australia and Chile.
- A pre-clinical research programme examining the effect of cannabinoids in breast, brain and pancreatic cancer. It has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer.

The Company has secured certain rights to medicinal cannabis based formulations and treatment protocols developed over many years by a California-based group (Aunt Zelda's) that has a very high profile within the USA and a growing international profile.